Ignite Creation Date:
2024-05-05 @ 5:21 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00434148
Status:
COMPLETED
Last Update Posted:
2016-03-08
First Post:
2007-02-09
Brief Title:
Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo Persistent or Recurrent Cushings Disease
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A Randomized Double-blind Study to Assess the Safety and Efficacy of Different Dose Levels of Pasireotide SOM230 Subcutaneous sc Over a 6 Month Treatment Period in Patients With de Novo Persistent or Recurrent Cushings Disease
Status:
COMPLETED
Status Verified Date:
2016-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the safety and efficacy of two different doses of Pasireotide in patients with de novo or recurrentpersistent Cushings Disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2006-004111-22 | EUDRACT_NUMBER | None | None |